Results 81 to 90 of about 43,912 (220)
The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA [PDF]
Alterations in genetic programs required for terminal myeloid differentiation and aberrant proliferation characterize acute myeloid leukemia (AML) cells.
Bozzoni, Irene +8 more
core +2 more sources
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova +2 more
wiley +1 more source
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek +26 more
wiley +1 more source
All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
A 78-year-old-male with chronic myeloid leukemia (CML) treated for seven years with dasatinib developed an acute promyelocytic leukemia complicated by disseminated intravascular coagulopathy. A promyelocytic blast crisis was diagnosed by demonstrating co-
Teresa A. Colvin +4 more
doaj +1 more source
Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. [PDF]
The Notch signaling pathway contributes to the pathogenesis of a wide spectrum of human cancers, including hematopoietic malignancies. Its functions are highly dependent on the specific cellular context. Gain-of-function NOTCH1 mutations are prevalent in
Chang, Yuan-I +20 more
core +1 more source
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena +31 more
wiley +1 more source
Key Clinical Message Promyelocytic leukemia is a known medical emergency and requires rapid diagnosis and expedient therapy with differentiating agents.
Sameer Sawhney +6 more
doaj +1 more source
Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. [PDF]
BACKGROUND: Findings from clinical trials and population-based studies have differed with regard to whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia (APL) has decreased in the era of all-trans retinoic acid and ...
Abrahão, Renata +4 more
core +1 more source
ABSTRACT Background Plant Homeodomain Finger Protein 6 (PHF6) gene mutations are rare in acute myeloid leukemia (AML), with unclear mechanisms and uncertain prognostic value. They may compromise risk stratification and treatment decisions. This study analyzed clinical features and survival outcomes in PHF6‐mutated AML patients, evaluating the impact of
Dongmei Wang +6 more
wiley +1 more source
Acute promyelocytic leukemia is a rare form of acute myeloid leukemia in which immature promyelocytes abnormally proliferate in the bone marrow. In most cases, the disease is characterised by the translocation t(15;17) (q24;q21), which causes the ...
Sara Frazzetto +16 more
doaj +1 more source

